You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Dow
Colorcon
Harvard Business School
Merck

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GC4419


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for GC4419?

GC4419 is an investigational drug.

There have been 10 clinical trials for GC4419. The most recent clinical trial was a Phase 1 trial, which was initiated on October 3rd 2018.

The most common disease conditions in clinical trials are Head and Neck Neoplasms, Stomatitis, and Mucositis. The leading clinical trial sponsors are Galera Therapeutics, Inc., INC Research, and INC Research Australia Pty Ltd.

There are three US patents protecting this investigational drug and thirteen international patents.

Recent Clinical Trials for GC4419
TitleSponsorPhase
Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung CancerGalera Therapeutics, Inc.Phase 2
Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult SubjectsGalera Therapeutics, Inc.Phase 1
ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck CancerGalera Therapeutics, Inc.Phase 3

See all GC4419 clinical trials

Clinical Trial Summary for GC4419

Top disease conditions for GC4419
Top clinical trial sponsors for GC4419

See all GC4419 clinical trials

US Patents for GC4419

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GC4419   Start Trial Methods for treatment of diseases GALERA LABS, LLC (Creve Coeur, MS)   Start Trial
GC4419   Start Trial Methods for treatment of diseases Galera Labs, LLC (Creve Coeur, MO)   Start Trial
GC4419   Start Trial Methods for treatment of diseases GALERA LABS, LLC (Creve Coeur, MO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GC4419

Drugname Country Document Number Estimated Expiration Related US Patent
GC4419 Australia 2012316397 2031-09-26   Start Trial
GC4419 Australia 2016247160 2031-09-26   Start Trial
GC4419 Australia 2019201392 2031-09-26   Start Trial
GC4419 Canada 2849456 2031-09-26   Start Trial
GC4419 China 103906756 2031-09-26   Start Trial
GC4419 European Patent Office 2760874 2031-09-26   Start Trial
GC4419 Hong Kong 1199261 2031-09-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
AstraZeneca
Moodys
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.